New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For DELL;ADNC;MRK;TSN;CTRP;GDOT;VVUS;NFLX;MCK;MAT;LTM;ALKS;ELN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>
December 22, 2014
08:08 EDTMRKNewLink Genetics, Merck awarded $30M contract for Ebola vaccine candidate
NewLink Genetics (NLNK) and Merck (MRK) announced that the Biomedical Advanced Research and Development Authority, or BARDA, of the United States Department of Health and Human Services, or HHS, has awarded NewLink Genetics' wholly-owned subsidiary, BioProtection Systems, as the prime contractor in a $30 million contract to support the manufacturing and development activities of its investigational rVSV-EBOV vaccine candidate, including clinical development through a new 330-person Phase Ib study. Pending the results of Phase I trials underway, the U.S. National Institutes of Health has announced plans to initiate, in early 2015, a large randomized, controlled Phase II/III study to evaluate the safety and efficacy of this and another investigational Ebola vaccine candidate.
07:32 EDTGDOTGreen Dot contract renewal with Wal-Mart likely, says Deutsche Bank
Subscribe for More Information
December 19, 2014
16:01 EDTNFLXOptions Update; December 19, 2014
iPath S&P 500 VIX Short-Term Futures down 27c to 29.90. Option volume leaders: AAPL TSLA TWTR AMZN FB C GILD BAC NFLX according to Track Data.
13:43 EDTTSNUSDA says bird flu found in backyard poultry in Oregon
The United States Department of Agriculture’s Animal and Plant Health Inspection Service confirmed the presence of highly pathogenic H5N8 avian influenza in guinea fowl and chickens from a small backyard poultry flock in Winston, Oregon. The H5N8 virus has not been found in commercial poultry anywhere in the United States and there is no immediate public health concern, as the H5N8 virus has been found in birds in other parts of the world and has not caused any human infection to date, the USDA stated. The Fly notes companies that offer or are developing flu vaccines include BioCryst (BCRX) and Novavax (NVAX). Publicly traded meat producers include Hormel Foods (HRL), Pilgrim's Pride (PPC), Sanderson Farms (SAFM) and Tyson Foods (TSN). Reference Link
08:07 EDTMRKMerck begins tender offer to acquire Cubist
Subscribe for More Information
December 18, 2014
16:01 EDTNFLXOptions Update; December 18, 2014
Subscribe for More Information
10:58 EDTMRKTetraphase seen as takeover target after antibiotic trial success
Subscribe for More Information
09:35 EDTNFLXActive equity options trading
Active equity options trading according to Track Data: AAPL FB TSLA PBR RAD AMAT NFLX GILD KMI TWTR
07:36 EDTMRKMerck acquires OncoEthix, terms include upfront payment of up to $110M
Subscribe for More Information
December 17, 2014
16:00 EDTNFLXOptions Update; December 17, 2014
Subscribe for More Information
11:14 EDTNFLXNetflix rises after MKM downplays production risks, DISH deal announced
Shares of Netflix (NFLX) are climbing after research firm MKM Partners recommended that investors buy shares of the online streaming service heading into the New Year. The shares could triple or quadruple over the next four to five years, the firm predicted. WHAT'S NEW: Some believe that Netflix's stepped up content production increases its risk, MKM analyst Rob Sanderson reported. However, Netflix's movie content purchase deals carry similar risk and the company's massive content portfolio insulates it from risk, the analyst stated. Meanwhile, Sanderson disagrees with initial reviews of Netflix's "Marco Polo" series. The series is no "Games of Thrones," but the season of "Marco Polo" as a whole is better than the first few episodes, Sanderson believes. Netflix should benefit more than expected from the advent of 4K resolution and the company should announce partnerships with cable companies at a faster rate next year, the analyst indicated. He continues to identify the stock as his favorite large-cap name and estimates that it could triple or quadruple over the next four or five years. WHAT'S NOTABLE: Satellite broadcaster DISH (DISH) earlier today announced that it had become the first major pay-TV provider in the U.S. to integrate the Netflix app into its set-top box. The app gives customers the ability to instantly stream Netflix movies and TV shows, DISH added. PRICE ACTION: In mid-morning trading, Netflix gained 3.4% to $327.21.
10:36 EDTMRKCowen pharmaceuticals analysts hold an analyst/industry conference call
Analyst Research Team discusses the imminent Merck/Cubist Zerbaxa opportunity and the Cempra SOLITAIRE-ORAL Trial readout on an Analyst/Industry conference call to be held on December 17 at 2 pm.
09:53 EDTNFLXDISH integrates Netflix into set-top box
DISH (DISH) today became the first major pay-TV provider in the U.S. to integrate the Netflix (NFLX) app into its set-top box. Available on DISH’s second-generation Hopper, the app gives customers the ability to instantly stream Netflix movies and TV shows, including “House of Cards” and “Orange is the New Black,” from the same platform used to access their linear television channels. The Netflix app will rollout to DISH customers throughout the day. The Netflix app is currently available on all broadband-connected second-generation Hopper set-top boxes. In the coming months, DISH expects the app to rollout to Joey, Super Joey and Wireless Joey clients. Additionally, in the future, titles available on Netflix could be integrated into the search functionality across live, recorded and Video On Demand programs for both the Hopper as well as DISH’s forthcoming OTT service.
09:41 EDTNFLXActive equity options trading
Subscribe for More Information
08:40 EDTNFLXNetflix shares should be bought into New Year, says MKM Partners
Subscribe for More Information
06:14 EDTALKSAlkermes price target raised to $72 from $60 at Citigroup
Subscribe for More Information
December 16, 2014
16:00 EDTNFLXOptions Update; December 16, 2014
iPath S&P 500 VIX Short-Term Futures up 1.55 to 34.60. Option volume leaders: AAPL TSLA TWTR AMZN FB C GILD BAC NFLX AA MGM MCD according to Track Data.
10:16 EDTLTMHigh option volume stocks:
Subscribe for More Information
09:36 EDTNFLXActive equity options trading
Active equity options trading according to Track Data: AAPL AMZN C TSLA PBR TWTR NFLX JPM CLF ABX
09:17 EDTNFLXInternet sector upgraded to Attractive from Neutral at Goldman
Goldman upgraded the Americas Internet sector to Attractive to Neutral based on more reasonable valuations, reduced expectations, and strong sector growth. As part of the sector change, the firm upgraded GrubHub (GRUB) to Buy from Neutral, downgraded Shutterfly (SFLY) to Neutral from Buy, and lowered Priceline (PCLN) to Buy from Conviction Buy.
08:47 EDTMRKHemispherx Ampligen provides anti-tumor activity
Subscribe for More Information
December 15, 2014
16:00 EDTNFLXOptions Update; December 15, 2014
Subscribe for More Information
11:42 EDTMCKMcKesson management to meet with FBR Capital
Field trip to company headquarters to be held in San Francisco on December 18 hosted by FBR Capital.
07:35 EDTVVUSApricus Biosciences appoints Barbara Troupin, M.D. as Chief Medical Officer
Subscribe for More Information
07:02 EDTALKSAlkermes announces initiation of Phase 1 aripiprazole lauroxil study
Subscribe for More Information
05:38 EDTCTRPTuniu announces $148M investment in aggregate from group of investors
Tuniu (TOUR) announced that it has entered into a share subscription agreement with Unicorn Riches Limited, a special purpose vehicle of Hony Capital, JD.com E-commerceHong Kong Corporation Limited, a special purpose vehicle of JD.com (JD), Ctrip Investment Holding, a subsidiary of Ctrip.com (CTRP) and the respective personal holding companies of Tuniu's CEO and COO, pursuant to which Tuniu will issue and sell a total of $148M newly issued class A ordinary shares to the investors. Pursuant to the agreement, Unicorn Riches Limited, JD.com E-commerce Hong Kong Corporation Limited, Ctrip Investment Holding and the personal holding companies of Dunde Yu, Tuniu's chairman of the board and CEO, and Haifeng Yan, Tuniu's director and COO, agree to subscribe newly issued Class A ordinary shares of the company in the amount of $50M, $50M, $15M, $16.5M and $16.5M, respectively. The purchase price will be $4.02 per ordinary share, or the equivalent of $12.06 per ADS. The purchase price represents the average closing trading prices of the company's ADSs for the ten trading days prior to the signing of the agreement, adjusted for ADS-to-ordinary share ratio, and represents a small premium over the average of ADS closing trading prices in the last five trading days. This share issuance is made in reliance on, and in compliance with, Regulation S under the Securities Act of 1933, as amended. Each of the investors has agreed not to sell, transfer or dispose of any shares acquired in the transaction for six months after the closing. In addition, the company also announced that it has decided not to pursue its proposed registered public offering of ADSs and will withdraw the related registration statement on Form F-1 previously filed with the SEC on December 2.
December 12, 2014
16:33 EDTMRKStocks finish week lower amid steep decline in oil prices
Subscribe for More Information
15:19 EDTGDOTGreen Dot files to sell 6.13M shares of Class A common stock for holders
Subscribe for More Information
14:56 EDTGDOTGreen Dot requests withdrawal of registration statement
The company requests withdrawal of the Registration Statement, File No. 333-200873, because it was inadvertently filed as form type “S-3” instead of form type “S-3ASR.” The company intends to file a new automatic shelf registration statement with the proper EDGAR codes to identify it as a filing on form type “S-3ASR” shortly after submitting this request.
12:22 EDTNFLXNetflix introduces Atlas telemetry platform
Subscribe for More Information
06:33 EDTNFLXNetflix responds to FCC Commissioner's fast lanes allegations, TechCrunch says
Subscribe for More Information
06:14 EDTGDOTGreen Dot files to sell 6.13M shares for holders
December 11, 2014
16:01 EDTNFLXOptions Update; December 11, 2014
Subscribe for More Information
09:37 EDTNFLXActive equity options trading
Subscribe for More Information
08:27 EDTMRKNewLink Genetics falls after Ebola vaccine trial suspended
Shares of NewLink Genetics (NLNK) are falling in pre-market trading after a clinical trial of the Ebola vaccine being developed by the company and partner Merck (MRK) was temporarily suspended as a precautionary measure after four patients complained of joint pains in their hands and feet, the University of Geneva Hospital said. The trials are scheduled to resume next month in up to 15 volunteers after checks to make sure that the joint pain symptoms were benign and temporary, the hospital added. Shares of NewLink are down 6.5% to $34.50 in early morning trading following the news, while Merck shares are indicated to open fractionally higher.
07:46 EDTMATBenchmark to hold a conference
Micro Cap Discovery Conference is being held in Chicago on December 11.
December 10, 2014
16:00 EDTMRKOptions Update; December 10, 2014
Subscribe for More Information
13:45 EDTMRKMerck's Gardasil 9 approved by FDA
Subscribe for More Information
12:06 EDTTSNUSDA lowers 2014 meat production forecast
Subscribe for More Information
09:53 EDTTSNTyson sees capturing over $500M in Hillshire synergies by end year three
Subscribe for More Information
09:49 EDTTSNTyson Foods reiterates temporary halt on China expansion plans
09:44 EDTTSNTyson Foods targeting consistent growth, less volatile earnings
Subscribe for More Information
09:25 EDTTSNTyson Foods lists 'rapid de-leveraging,' acquisitions among cash priorities
Tyson Foods said its priorities for cash include rapid de-leveraging from $1B+ cash flows and $500M+ from sale of Latin American operations; acquisitions to fulfill its growth strategy; and returning cash to shareholders through share repurchases and dividends.
09:19 EDTTSNTyson Foods repeats FY15 adjusted EPS view $3.30-$3.40, consensus $3.41
Subscribe for More Information
08:47 EDTMRKMerck, IBCSG, BIG announce opening of PANACEA study
The International Breast Cancer Study Group, Breast International Group, and Merck announced the opening of the PANACEA study, a global collaborative study exploring a new way to treat HER2+ breast cancer that has become resistant to the current standard of care. The PANACEA study will investigate the use of pembrolizumab in combination with trastuzumab to evaluate whether the addition of an anti-PD-1 therapy can reverse trastuzumab resistance in patients with HER2+ breast cancer whose cancer has spread while on trastuzumab therapy. The trial, “Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2+ Breast Cancer,” is a Phase 1b/2 study in patients with HER2+ breast cancer whose cancer has spread while on treatment with trastuzumab. Primary outcome measures of the study are recommended dose and efficacy and safety profile of pembrolizumab in combination with trastuzumab. Response will be assessed by RECIST 1.1 criteria. Secondary outcome measures include safety and tolerability, disease control, duration of response, time to progression, progression-free survival and overall survival. The study is enrolling adult females with unresectable or metastatic breast adenocarcinoma with confirmed HER2-positivity. There are 10 sites participating in the study across Europe and Australia: Peter MacCallum Cancer Centre and Westmead Hospital in Australia; Medical University of Vienna in Austria; Jules Bordet Institute and CHU Sart Tilman in Belgium; Institut de Cancérologie de l’OUEST, Centre Léon Bérard and Institut Gustave Roussy in France; and Istituto Europeo di Oncologia Milano and Azienda USL4 Prato in Italy.
08:32 EDTMRKMerck announces early findings showing 18.5% overall response rate with Keytruda
Merck announced early study findings demonstrating an overall response rate of 18.5% with KEYTRUDA, the company’s anti-PD-1 therapy, as assessed by RECIST v1.1, central review in PD-L1 positive, advanced triple-negative breast cancer – one of the most aggressive forms of breast cancer. At the time of analysis, the median duration of response had not been reached with three of five responders on therapy for 11 months or more. These early findings, from the ongoing Phase 1b KEYNOTE-012 study, were shared today for the first time as part of the official press program at the 2014 San Antonio Breast Cancer Symposium and will be presented in an oral session at 10:45 a.m. CST by Dr. Rita Nanda, the University of Chicago. Data presented were from a cohort of the ongoing Phase 1b KEYNOTE-012 study which evaluated KEYTRUDA monotherapy at 10 mg/kg every two weeks in patients with advanced TNBC whose tumors were determined to be positive for PD-L1 expression. As measured by Merck’s proprietary PD-L1 immunohistochemistry clinical trial assay, tumors were considered to be PD-L1 positive if staining was present in the stroma or in greater than or equal to one percent of tumor cells. In the study, 58 percent of patients screened had tumors determined to be positive for PD-L1 expression. Most patients enrolled in this study had received two or more prior chemotherapies for metastatic disease and 87.5 percent had received prior neo-adjuvant or adjuvant therapy.
05:35 EDTCTRPTuniu, Ctrip.com sign strategic collaboration agreement
Tuniu (TOUR) announced that the company has signed a strategic agreement with Ctrip.com (CTRIP) to expand their collaboration on shared travel resources. In May, Ctrip acquired $15M of Tuniu Class A ordinary shares concurrent with Tuniu's IPO and currently owns over 3% of Tuniu's outstanding shares.
December 9, 2014
16:28 EDTMRKOn The Fly: Closing Wrap
Stocks on Wall Street opened in the red on the heels of a sharp sell-off in China and amid continued concern over tumbling oil prices. The domestic economic calendar offered little in the way of a catalyst and the market moved in a narrow range throughout the morning. However, the averages began to pare their losses once the European markets closed. By mid-afternoon the averages had turned mixed with the Nasdaq higher, the S&P flat, and the Dow the laggard, which is the way the trading day closed. ECONOMIC EVENTS: In the U.S., the National Federation of Independent Business' optimism index rose to 98.1 from a prior reading of 96.1. The JOLTS report showed job openings increased 149K to 4.83M in October, which was above the expectation for 4.795M openings. Wholesale sales increased 0.2% in October and inventories grew 0.4%, both of which were better than expected. In Asia, China's Shanghai composite index plunged 5.4%, making for the stock market's sharpest selloff in years, after the country’s securities clearing house raised the threshold for the type of collateral used for short-term loans and policymakers warned about potentially slower economic growth. In Europe, Greek stocks and bonds also tumbled after a move to bring forward presidential elections, which could potentially derail Greece’s bailout and austerity efforts. COMPANY NEWS: Verizon (VZ) was among the Dow's worst performers, sinking $1.98, or 4.05%, to $46.92 after the company warned that Q4 impacts of its promotional offers, together with the strong customer volumes this quarter, will put short-term pressure on its earnings per share. After last night's commentary from the company, Robert W. Baird downgraded Verizon shares to Neutral from Outperform and lowered its price target on the stock to $50 from $54... Merck (MRK) also weighed on the Dow, as the drugmaker fell $1.87, or 3.02%, to $60.01 after a Delaware court denied Cubist's (CBST) bid to stop Hospira (HSP) from selling a generic version of Cubicin in 2016. Merck announced just yesterday morning that it had agreed to buy Cubist in a transaction with a total value of approximately $9.5B. The news is a "tough start" to Merck's takeover and makes the $9.5B buyout price look $2B to $3B too high, according to analysts at Leerink. Shares of Cubist also fell $xxx, or xxx%, to $xxx following the court ruling. MAJOR MOVERS: Among the notable gainers was bluebird bio (BLUE), which surged $35.39, or 72.39%, to $84.28 after the company announced data from eight subjects treated with its LentiGlobin drug product and Piper Jaffray more than doubled its price target for the shares to $112 from $52. Among the noteworthy losers was Conn's (CONN), which plunged $14.26, or 40.64%, to $20.83 after unexpectedly reporting losses for its third fiscal quarter, withdrawing its FY15 guidance and announcing the departure of its CFO. Also lower was Spirit Airlines (SAVE), which slid $10.70, or 12.67%, to $73.77 after the company said last night that since late October there has been compression in the fare structure for close-in bookings, believed to be driven by the industry’s willingness to trade lower fuel prices for lower fares. Also, this morning, Raymond James downgraded Spirit Airlines to Market Perform from Outperform, citing valuation, European deflation headwinds, and earnings that are still being revised down. INDEXES: The Dow fell 51.28, or 0.29%, to 17,801.20, the Nasdaq rose 25.77, or 0.54%, to 4,766.46, and the S&P 500 slipped 0.49, or 0.02%, to 2,059.82.
16:00 EDTNFLXOptions Update; December 9, 2014
Subscribe for More Information
13:08 EDTMRKMerck may have paid $2B-$3B too much for Cubist, analyst says
Subscribe for More Information
12:29 EDTTSNTyson Foods volatility at low end of range into investor meeting
Subscribe for More Information
12:25 EDTMRKOn The Fly: Midday Wrap
Subscribe for More Information
11:48 EDTNFLXStocks with call strike movement; NFLX TSLA
Subscribe for More Information
11:29 EDTNFLXDiscovery CEO says international market 'steady, good' for company
Subscribe for More Information
10:32 EDTNFLXNetflix hits a fresh 6-month low, levels to watch
Subscribe for More Information
10:10 EDTMRKMerck trades sharply lower, levels to watch
The stock is down over 4.3% to $59.23 at time of writing. At that price next support is at $57.95. Resistance is at $60.25.
08:25 EDTMRKBristol-Myers data positive, says BMO Capital
Subscribe for More Information
08:23 EDTMRKMerck has 'no way out' of Cubist deal after court decision, says Leerink
Subscribe for More Information
08:12 EDTMRKMerck still sees Cubist acquisition neutral to modestly accretive to 2015 EPS
Merck (MRK) issued the following statement regarding the decision of the U.S. District Court for the District of Delaware. The decision, which upheld the patent for CUBICIN that expires on June 15, 2016 and invalidated four others, is subject to appeal. The company continues to believe the acquisition of Cubist (CBST) will create strong fundamental value for Merck’s shareholders. The combined strength of both companies will provide both incremental and long-term value, and Merck expects the transaction to add more than $1B of revenue to its 2015 base, with strong growth potential thereafter. The court’s decision does not change Merck’s expectation that the transaction will be neutral to modestly accretive to 2015 non-GAAP EPS. The company also continues to expect that the transaction will contribute mid-single digit accretion on a percentage basis to non-GAAP EPS in 2016, and will continue to be accretive thereafter.
08:11 EDTMRKCubist downgraded to Sector Perform from Outperform at RBC Capital
Subscribe for More Information
06:48 EDTNFLXNetflix wants to be 'completely global' within five years, GigaOM reports
Netflix Chief Content Officer Ted Sarandos told investors at the UBS Global Media and Communications Conference that the company wants to be "completely global" and available everywhere in the world before 2020, GigaOM reports. CEO Reed Hastings has previously said that the company could eventually generate up to 80% of its revenue outside the U.S. Reference Link
December 8, 2014
19:00 EDTMRKCubist CEO says Cubicin patent ruling will not affect Merck transaction
Subscribe for More Information
18:00 EDTMRKCubist loses bid to stop Hospira's generic Cubicin after 2016, Bloomberg says
Cubist's (CBST) patent for Cubicin that expires in June 2016 upheld by judge, Bloomberg added. Note that this morning Merck (MRK) and Cubist Pharmaceuticals announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash.
17:54 EDTMRKFour Cubist Cubicin patents invalidated as Hospira wins ruling, Bloomberg says
Subscribe for More Information
17:30 EDTMRKMerck acquisition of Cubist could be a 'winner', Barron's says
Subscribe for More Information
17:30 EDTMRKMerck shares lower after reports of judge decision in Cubist/Hospira case
Subscribe for More Information
16:24 EDTMRKOn The Fly: Closing Wrap
Stocks on Wall Street were lower amid another drop in crude oil prices, which tumbled to five-year lows. The market opened slightly lower following weaker than expected data from China and Japan, with nothing of note on the domestic calendar to get buyers involved in the day’s activity. Near noon, the averages gained downside momentum and though the market pared its losses several times, it was never able to gain any steam to pull the indexes back into the green. ECONOMIC EVENTS: In the U.S., no major economic data was released. In Asia, Chinese exports rose 4.7% from a year earlier in November, which missed the consensus estimate for an 8% increase. Chinese imports fell 6.7% from the prior year last month, compared with projections for a 3.8% increase. Additionally, Japan's revised third quarter gross domestic product estimate showed the economy shrank more than initially thought, with growth contracting an annualized 1.9%. COMPANY NEWS: Shares of Cubist Pharmaceuticals (CBST) surged $26.24, or 35.29%, to $100.60 after Merck (MRK) agreed to acquire the maker of next-generation antibiotics for $102 per share in cash, or $8.4B and the assumption of $1.1B in debt. A number of other antibiotic makers also climbed, including Tetraphase (TTPH), which rose $2.45, or 8.82%, to $30.24, and Cempra (CEMP), which advanced $1.64, or 11.37%, to $16.06, while shares of Merck finished fractionally higher, adding 39c, or 0.63%, to $61.88 following the deal announcement. MAJOR MOVERS: Among the notable gainers following their presentations at the American Society of Hematology, or ASH, annual meeting were Calithera Biosciences (CALA), which gained $2.38, or 22.52%, to $12.95, and Acceleron Pharma (XLRN), which jumped $5.11, or 13.6%, to $42.67. Among the noteworthy losers was McDonald's (MCD), which fell $3.70, or 3.84%, to $92.61 after the Dow member reported a 2.2% decline in global same-restaurant sales in November. Additionally, the fast-food giant warned that its fourth quarter results would be hurt by its sales pressures, supplier issues in China and a stronger U.S. dollar. Also lower were shares of Liquidity Services (LQDT), which plunged $2.77, or 27.0%, to $7.49 after the company disclosed that Wal-Mart (WMT) had terminated a deal to provide it with surplus merchandise. INDEXES: The Dow fell 106.31, or 0.59%, to 17,852.48, the Nasdaq dropped 40.06, or 0.84%, to 4,740.69, and the S&P 500 slipped 15.06, or 0.73%, to 2,060.31.
16:24 EDTMRKAmgen initiates new combination trial for talimogene laherparepvec with KEYTRUDA
Subscribe for More Information
13:12 EDTMRKMerck paid full price but made good deal for Cubist, says UBS
Subscribe for More Information
12:40 EDTMRKOn The Fly: Midday Wrap
Subscribe for More Information
12:25 EDTMRKAntibiotic makers rise after Merck agrees to buy Cubist
Subscribe for More Information
11:30 EDTMCKLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
11:29 EDTNFLXNetflix falls to session lows, levels to watch
The shares are down over 2% to $342.44. At that price next support is at $340.05. Resistance is at $345.45.
10:00 EDTNFLXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:50 EDTALKSAlkermes price target raised to $63 on pipeline catalysts at Credit Suisse
Subscribe for More Information
08:30 EDTMRKMerck says deals with Cubist includes $250M break-up fee clause
Subscribe for More Information
08:21 EDTMRKMerck says looked at all risks, including patent litgation, before Cubist deal
Subscribe for More Information
08:11 EDTMRKCubist volatility elevated into Merck acquiring for $8.4B in cash
Subscribe for More Information
08:08 EDTMRKMerck says about $9.5B of debt to be issued related to Cubist deal
Subscribe for More Information
07:35 EDTMRKAdvaxis reports FDA acceptance of IND application for ADXS-PSA combination trial
Subscribe for More Information
07:13 EDTMRKMerck to host conference call
Subscribe for More Information
07:01 EDTMRKMerck to acquire Cubist for $102 per share in cash, or $9.5B
Subscribe for More Information
07:00 EDTMRKMerck to acquire Cubist for $102 per share in cash
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use